ASIA unversity:Item 310904400/16366
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 90570/105786 (86%)
造访人次 : 16376997      在线人数 : 338
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻


    题名: Drug Design for XRCC4 in Silico
    作者: 蔡輔仁;Tsai, Fuu-Jen;蔡長海;陳語謙;Chen, Calvin Yu-chian
    贡献者: 生物科技學系
    日期: 2009-10
    上传时间: 2012-11-23 17:12:05 (UTC+8)
    摘要: XRCC4-DNA ligase IV complex is critical in non-homologous end-joining DNA repair system. Inhibition of its formation is potential in cancer cell killing, while no related study was reported. Herein, the structure-based drug design was used to develop potent compounds in this study. Firstly, the Traditional Chinese Medicine database was employed to dock into the binding site of XRCC4; then the top 10 output compounds were regarded as the scaffolds for further de novo evolution. Secondly, 99 diversities outcome were screened by Lipinski's Rule (rules of five) and the survivors were put into the second round of docking study. As a result, diversities with higher DockScore than the top 10 of DockScore from the first round were selected for pose analysis. Finally, 8 diversities were suggested to behave strongest inhibitory effects on XRCC4-DNA ligase IV complex formation. The 8 candidates selected by this study may serve as potent personalized anticancer drugs.
    關聯: IEEE/ACM Transactions on Computational Biology and Bioinformatics
    显示于类别:[生物科技學系] 期刊論文


    档案 描述 大小格式浏览次数


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈